Team develops new process for evaluating impacts of gene edits that alter rather than ‘knock out’ DNA code
Gut infection outbreaks halved during first 6 months of COVID-19 pandemic in UK
21 March 2022A psychedelic drug, combined with intense therapy, improves PTSD symptoms
22 March 2022Team develops new process for evaluating impacts of gene edits that alter rather than ‘knock out’ DNA code
A new study from scientists at ChristianaCare’s Gene Editing Institute is advancing the safety and efficacy of using CRISPR gene editing in patient treatments by demonstrating how to identify and evaluate the broad-based biological impact of gene editing on targeted tissues, where the edits are designed to fully disable or “knock out” a specific sequence of genetic code. The work, published today in the Nature journal Gene Therapy, supports the Institute’s efforts to improve lung cancer treatments by using CRISPR to disable or alter a master regulator gene to prevent it from producing a protein that blunts the impact of chemotherapy.
